Clinical Trial Update: Effects of Interleukin-1 Receptor Antagonism on Hyperandrogenemia in Women With Polycystic Ovary Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating interleukin-1 receptor antagonism for reducing hyperandrogenemia in women with polycystic ovary syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycystic Ovary Syndrome

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Polycystic Ovary Syndrome | Phase 2 | Status: COMPLETED